Kristen Quigley
Director de Operaciones en MOLECULAR TEMPLATES, INC. .
Cargos activos de Kristen Quigley
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Director de Operaciones | 02/08/2023 | - |
Corporate Officer/Principal | 01/01/2017 | 02/08/2023 |
Historial de carrera de Kristen Quigley
Antiguos cargos conocidos de Kristen Quigley.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Director de Operaciones | - | - |
Formación de Kristen Quigley.
Washington University in St. Louis | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Chief Operating Officer | 2 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Bolsa de valores
- Insiders
- Kristen Quigley
- Experiencia